Akio Horiguchi

Dr. Akio Horiguchi

Associate Professor, Department of Urology, National Defense Medical College
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2010 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
Akio HoriguchiAkio Horiguchi
Akio Horiguchi
TAT Asano
T Asano
KKK Kuroda
K Kuroda
ASA Sato
A Sato
JAJ Asakuma
J Asakuma
MSM Sumitomo
M Sumitomo
Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes that mediate cell survival, proliferation, and angiogenesis and is aberrantly activated in various types of malignancies, including renal cell carcinoma (RCC). We examined whether it could be a novel therapeutic target for RCC by using the STAT3 inhibitor WP1066. The antitumour activities and related mechanisms of WP1066 were investigated in vitro on renal cancer cell lines and in vivo on murine xenografts. In Caki-1 and 786-O renal cancer cells, 5 μM WP1066 prevented the phosphorylation of STAT3, and 2.5 μM WP1066 significantly (P<0.01) inhibited cell survival and proliferation. WP1066 suppressed the expression of Bcl-2, induced apoptosis, and inhibited the basal and hypoxia-induced expression of HIF1α and HIF2α, as well as vascular endothelial growth factor secretion into cell culture medium. Human umbilical vascular endothelial cells cocultured with media from WP1066-treated cells showed significantly reduced tubulogenesis (P<0.05). Systemic oral administration of WP1066 to mice for 19 days significantly inhibited the growth of Caki-1 xenograft tumours (P<0.05), and pathological analysis of xenografts of WP1066-treated mice showed decreased immunostaining of phosphorylated STAT3 and reduced length of CD34-positive vessels (P<0.05). Our results suggest that using WP1066 to inhibit the STAT3 signalling pathway could be a novel therapeutic strategy against RCC.


1 October 2017 in Urology
Verified
Journal Article
Closed access
Akio HoriguchiAkio Horiguchi
Akio Horiguchi
MSMasayuki Shinchi
Masayuki Shinchi
ANAkiko Nakamura
Akiko Nakamura
TWTakatsugu Wada
Takatsugu Wada
KIKeiichi Ito
Keiichi Ito
MIMiya Ishihara
Miya Ishihara

23 October 2015 in The Prostate
Verified
Journal Article
Closed access
PDF file
Akio HoriguchiAkio Horiguchi
Akio Horiguchi
KTKazuhiro Tsujita
Kazuhiro Tsujita
KIKaku Irisawa
Kaku Irisawa
TKTadashi Kasamatsu
Tadashi Kasamatsu
KHKazuhiro Hirota
Kazuhiro Hirota
MIMiya Ishihara
Miya Ishihara

1 February 2018 in Journal of Urology
Verified
Journal Article
Closed access
Akio HoriguchiAkio Horiguchi
Akio Horiguchi
MSMasayuki Shinchi
Masayuki Shinchi
AMAyako Masunaga
Ayako Masunaga
KIKeiichi Ito
Keiichi Ito
TATomohiko Asano
Tomohiko Asano
RARyuichi Azuma
Ryuichi Azuma
We examined the impact on urethral stricture complexity at urethroplasty of previous transurethral treatments such as dilation, urethrotomy and stenting, which are most commonly performed when treating male urethral stricture. We retrospectively reviewed the records of 45 males who had undergone transurethral treatments before urethroplasty. We compared urethrography findings at initial diagnosis with those at urethroplasty. Males with failed hypospadias repair, lichen sclerosis or a history of prior urethroplasty were excluded from analysis. We considered stricture complexity increased if the number and/or length of strictures on urethrography at urethroplasty was greater than that at initial diagnosis or false passage was newly identified. Of the patients 39 (87%), 32 (71%) and 13 (29%) had undergone urethral dilation, urethrotomy and urethral stenting, respectively, and 39 (87%) had undergone repeat or multiple kinds of transurethral treatments. Stricture complexity was increased in 22 men (49%) while 7 (16%) required urethroplasty more complex than that anticipated from urethrography findings at initial diagnosis. Increased stricture complexity was significantly associated with a history of urethrotomy (p = 0.03), urethral stenting (p = 0.0002) and repeat transurethral treatments (p = 0.01). Multivariate analysis revealed that urethral stenting (p = 0.01) and repeat transurethral treatments (p = 0.01) were independent predictors of increased stricture complexity. Repeat transurethral treatments increase stricture complexity and are potentially counterproductive. Even a single application of temporary urethral stenting carries a high risk of complicating the stricture and requiring complex urethroplasty.

1 April 2017 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
YTYujiro Tsujita
Yujiro Tsujita
Akio HoriguchiAkio Horiguchi
Akio Horiguchi
STShinsuke Tasaki
Shinsuke Tasaki
MIMakoto Isono
Makoto Isono
TATakako Asano
Takako Asano
TKToshihiro Kushibiki
Toshihiro Kushibiki
Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes mediating cell survival, proliferation and angiogenesis and is aberrantly activated in various types of malignancies, including bladder cancer. We examined whether it could be a novel therapeutic target for bladder cancer using the STAT3 inhibitor WP1066. In T24 and UMUC-3 bladder cancer cells, 5 µM WP1066 prevented the phosphorylation of STAT3 and 2.5 µM WP1066 decreased cell survival and proliferation significantly (P<0.01). WP1066 also induced apoptosis accompanied by the suppression of the expression of Bcl-2 and Bcl-xL in T24 cells. Moreover, the covered area in a wound and the number of cells invading through a Matrigel chamber decreased significantly (P<0.01) when cells were treated with WP1066. The activities of MMP-2 and MMP-9 were also decreased by treatment with 10 µM WP1066. Our results revealed that using WP1066 to inhibit the STAT3 signaling pathway suppressed the viability and invasiveness of bladder cancer cells effectively and could be a novel therapeutic strategy against bladder cancer.